CLDN18.2-postive

Beyond's analysis on CLDN18.2-postive

• 2026-08-25 — Astellas initiates Phase 3 trial of ASP2138 for CLDN18.2-positive gastric cancer, advancing its oncology pipeline

Recent news mentioning CLDN18.2-postive

• 2026-08-24 — Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Appears alongside

• Astellas Doses First Patient
• Phase
• Study
• ASP2138
• HER2-negative

Browse the full archive →